



ADW

TMH 6/3/04 6565-66400-01
31-10

PATENT
Attorney Reference Number 6565-66400-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chaw et al.

Application No. 10/622,316

Filed: July 18, 2003

Confirmation No. 4339

For: SUSTAINED RELEASE FORMULATION
FOR CARBAMATES AND A METHOD
THEREFOR

Examiner:

Art Unit:

Attorney Reference No. 6565-66400-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed June 3, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
- ☒ Form 1449 and references cited thereon (15)

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed. Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing



TMW 06/03/04 6565-66400-01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chaw et al.

Application No. 10/622,316

Filed: July 18, 2003

Confirmation No. 4339

For: SUSTAINED RELEASE FORMULATION
FOR CARBAMATES AND A METHOD
THEREFOR

Examiner:

Art Unit:

Attorney Reference No. 6565-66400-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed June 3, 2004

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

If the present application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55). Applicants will provide copies of such patents upon request.

Applicants are filing this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. It is believed that no fee is due to file this IDS. If the


Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



FORM PTO-159 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) 6565-66400	Application Number 10/622,316
	Applicant CHENG SHU CHAW ET AL.	
	Filing Date July 18, 2003	Group Art Unit 1615

U.S. PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,430,030	Jul. 4/95	Sömmmer et al.	514	221	
	6,264,974	Jul. 24/01	Madhat	424	434	
	4,278,667	Jul. 14/81	Madison et al.	424	232	
	4,278,679	Jul. 14/81	Madison et al.	424	263	
	5,298,504	Mar. 29/94	Sömmmer et al.	514	221	
	5,939,095	Aug. 17/99	Hille et al.	424	449	
	6,114,347	Sep. 5/00	Hille et al.	514	297	
	5,480,651	Jan. 2/96	Callaway	424	464	
	6,004,582	Dec. 21/99	Faour et al.	424	473	

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	C. S. Chaw, C-W Tan, Y. Y. Yang, L. Wang and S. Moochhala. Design of physostigmine-loaded polymeric microparticles for pretreatment against exposure to organophosphate agents, <i>Biomaterials</i> , Volume 24, Issue 7, (2003), 1271-1277
	C Chaw, Y Yang, S Moochhala. Preparation, characterization, in vitro evaluation of physostigmine loaded POE and POE /PLGA blend sub micron spheres fabricated by spray drying, CRS conference paper, 2002
	B Zhao, S. M. Moochhala, C. S. Chaw, Y. Y. Yang. Simple liquid chromatographic method for the determination of physostigmine and its metabolite eseroline in rat plasma: application to a pharmacokinetic study, <i>Journal of Chromatography B</i> , 784 (2003), 323-329
	K. Tuovinen, E. Kaliste-Korhonen, F. M. Raushel, O. Hänninen, Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication, <i>Toxicology</i> 134 (1999) 69-178.
	S. A. Miller, D. W. Blick, S. Z. Kerenyi, M. R. Murphy, Efficacy of physostigmine as a pretreatment for organophosphate poisoning, <i>Pharmacol. Biochem. Behav.</i> 44 (2) (1993) 343-347.
	K. Walter, M. Muller, M. F. Barkworth, A. V. Nieciecki, F. Stanislaus, Pharmacokinetics of physostigmine in man following a single application of a transdermal system, <i>Br. J. Clin. Pharmacol.</i> 39 (1995) 59-63.
	P. Hartvig, L. Wiklund, E. Lindström, Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients, <i>Acta Anesthesiol. Scand.</i> 30 (1986) 177-182.
	S. M. Somani, S. N. Dube, Physostigmine --- an overview as pretreatment drug for organophosphate intoxication, <i>Int. J. Clin. Pharmacol Ther Toxicol.</i> 27 (8) (1989) 367-387.
EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) 6565-66400	Application Number 10/622,316
	Applicant CHENG SHU CHAW ET AL.	
	Filing Date July 18, 2003	Group Art Unit 1615

U.S. PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>	
	F. Pavanetto, I. Genta, P. Giunchedi, B. Conti, Evaluation of spray drying as a method for polylactide and polylactide-co-glycolide microsphere preparation, J. Microencapsulation 10 (4) (1993) 487-497.
	M. D. L. Moretti, E. Gavini, C. Juliano, G. Pirisino, P. Giunchedi, Spray-dried microspheres containing ketoprofen formulated into capsules and tablets, J. Microencapsulation 18 (1) (2001) 111-121.
	P. O'Hara, A. J. Hickey, Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization, Pharm. Res. 17 (8) (2000) 955-961.
	B. Baras, M. A. Benoit, J. Gillard, Parameters influencing the antigen release from spray-dried poly(DL-lactide) microparticles, Int. J. Pharm. 200 (1) (2000) 133-145.
	Takada H, Uda Y, Toguchi H, Ogawa Y. Application of a spray drying technique in the production of TRH-containing sustained release microparticles of biodegradable polymers. PDA J Pharm Sci & Tech 1995; 49:180-184.
	Perugini P, Genta I, Conti B, Modena T, Pavanetto F. Long-term release of clodronate from biodegradable microspheres. AAPS PharmSciTech 2001; 2(3) Article 10
	Rubnov S, Levy D, Schneider H. Liquid chromatographic analysis of physostigmine salicylate and its degradation products. J Pharm Biomed Ana 1999; 18:939-945
EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	